News
When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?
In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA) treatment is an important prognostic indicator. To identify patients with an insufficient response to this modality who require second-line therapy, the best practice is to assess the biochemical response to UDCA after 12 months of treatment. A validated and easy-to-use tool is the determination of serum alkaline phosphatase (ALP) activity and serum total bilirubin concentration. Although treatment response to UDCA is commonly checked after 12…
Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV…
Patient with Diabetes: When to Follow Up and When to Refer to a Specialist?
It is most often the general practitioner (GP) who first diagnoses diabetes. Whether during…
Adding Paracetamol to Tramadol to Relieve Early Postoperative Pain After Lumbar Discectomy
A recently published study is likely the first prospective randomized controlled trial comparing…
Prediction of Ischemic Stroke Risk in Patients with Rheumatoid Arthritis Using a Simplified Score
Ischemic strokes (iCMP) are a common cause of death or significant disability in developed…
The Wound Healing Process Step by Step and What Can Complicate It
Proper care of injuries is a fundamental prerequisite for their successful healing. Knowing the individual...
Hope Awakens with Early Diagnosis of Parkinson's Disease Based on Skin Odor
According to scientists from the United Kingdom, a simple test based on an individual's skin odor could...
Deep stimulation of the globus pallidus improved clinical symptoms in a patient with refractory parkinsonism and genetic mutation
The authors of the presented work studied the effects of deep brain stimulation (DBS) in a patient with...
ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively…
Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis
An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic…